Introduction
============

In 2010, the Centers for Disease Control and Prevention (CDC) released the US Medical Eligibility Criteria for Contraceptive Use (MEC) to guide health care providers in making evidence-based decisions on contraception. MEC focused on 20 medical conditions that present an increased risk for adverse outcomes during pregnancy, stating that long-acting, highly effective contraception methods may be the best choice for women with these medical conditions ([@R1]). Such methods include reversible options, such as intrauterine devices (IUDs) and implants, and permanent options, such as sterilization. Sole use of behavior-based methods, such as condoms, was not recommended because of their typically high failure rates.

CDC disseminated MEC guidelines through mobile applications, publications, and presentations ([@R2]). Nevertheless, a recent survey found that providers' knowledge of MEC was low ([@R3]). Some studies of women with the 20 MEC medical conditions found low levels of use of highly effective contraception, high levels of unintended pregnancy, and provider-imposed limitations to effective contraception options ([@R4]--[@R7]).

MEC guidelines may be particularly relevant for providers who serve low-income women, including women enrolled in Medicaid. Such women are most likely to have unintended pregnancies ([@R8]) and associated medical conditions ([@R9]). In 2016 over 20% of reproductive-aged women in the United States were insured by Medicaid ([@R10]), and in 2010 Medicaid covered health care for nearly half of all US births ([@R11]). However, information comparing provision of contraception before and after MEC's release is unavailable. The objective of our study was to examine provision of contraception to women enrolled in Medicaid who had 1 or more of the 20 MEC-highlighted medical conditions by 1) determining the provision of family planning for these women and 2) comparing the use of highly effective contraception methods in the 2-year period before MEC's release (2008 and 2009) with their use in the 2 years after its release (2011 and 2012) to see if an increase occurred.

Methods
=======

Data sources
------------

We used Medicaid Analytical Extract (MAX) medical claims acquired from the Centers for Medicare and Medicaid Services (CMS) for the years 2008 through 2012. The MAX data set consists of individual-level claims data for all Medicaid-enrolled beneficiaries. We examined enrollees from 14 states, which accounted for more than 50% of all Medicaid enrollees in the United States: 10 southeastern states (Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, and Texas) and 4 states from other regions of the country (California, Minnesota, New York, and Pennsylvania). The Southeast was chosen as a focal point because its states are similar to each other in contraception health policy ([@R12]) and spending levels for Medicaid ([@R13]), and the health rankings of these states are among the lowest in the country ([@R14]). The other 4 states chosen were highly populous states from regions of the country that have various health policies and reimbursement levels that represent differences across the United States.

We obtained approvals to perform our research from CMS and from the institutional review board of the Georgia Institute of Technology. The study infrastructure to safeguard identifiable data followed the CMS-approved data use agreement, which allows publication of results from populations of 11 or more people (eg, patients).

Study population
----------------

We assessed the overall population of reproductive-aged women who were enrolled in Medicaid in 2008, 2009, 2011, and 2012 in all 14 states. We investigated 2 periods: the 2 years before MEC's release (2008 and 2009) and the 2 years after MEC's release (2011 and 2012). Our study population was a subset of the overall population and consisted of women aged 15 to 44 who had 1 or more of the 20 conditions listed in MEC ([Appendix A](#appA){ref-type="app"}). We did not count women more than once if they had multiple conditions. We stratified the study population by 1) age group (15--24 y, 25--34 y, 35--44 y) ([@R15]), 2) medical condition, and 3) state of residence. We obtained the age of each woman by using the date of birth in MAX's Personal Summary table. A woman was assigned to an age group on the basis of her age at the beginning of each period (2008 and 2011).

Medical condition was defined as 1 of the 20 MEC-identified conditions. A woman with a nonsurgical MEC condition was identified as having at least 3 Medicaid claims for that condition recorded on 3 different days in the before-MEC period (2008 and 2009) or the after-MEC period (2011 and 2012) ([@R16]). The Medicaid claim could be a claim from MAX's Other Therapy table or MAX's Inpatient table. Diagnosis codes of the *International Classification of Disease*, ninth edition (ICD-9) were used to identify nonsurgical conditions ([Appendix A](#appA){ref-type="app"}) ([@R17]). Different approaches were needed to identify women with surgical MEC conditions (bariatric surgery and solid organ transplant). To identify these women, we queried the Inpatient table of the MAX data for claims that contained the corresponding surgery condition procedure codes ([Appendix A](#appA){ref-type="app"}). We screened for the procedure codes in the inpatient claims that occurred in the 2 periods and assigned women to the period in which the surgery occurred. When identifying patients, we considered each condition separately, to account for comorbidities.

We identified the woman's state of residence by the state listed on her claim. This ensured that a woman was counted in each state in which she received service.

Outcome analysis
----------------

We considered 2 outcome measures, family planning management (FPM) and highest efficacy methods (HEMs). We documented the number of women for both outcome measures for both periods and for each medical condition.

**Family planning management**. We defined an FPM claim as one containing a diagnosis code beginning with V25, the overarching code for "encounter for contraceptive management" ([@R17]). The FPM measure includes many forms of contraception claims, ranging from discussion of contraception options with the clinician to procedures, such as inserting IUDs and sterilization. We aggregated the number of women with V25 claims for each period and each condition and compared the study population with the overall population. We considered 19 of the 20 MEC medical conditions; we excluded schistosomiasis because the number of women with these conditions was less than 11.

**Highest efficacy method, aggregate and condition-level analysis.**The HEM outcome consisted of contraception claims for IUDs, contraceptive implants, and sterilizations. MEC recommends HEMs for women with high-risk conditions. We used the diagnosis codes for IUD insertion (V25.1), IUD surveillance (V25.42), and implant surveillance (V25.43) and searched through both inpatient and other therapy claims. Because of the nature of the procedure, we searched for sterilizations (V25.2) through inpatient claims only.

We calculated HEM provision for the overall population, the study population, and each medical condition, including the number of women in the HEM outcome for each condition, the percentage rates of HEM, and the results of a 1-sided test for significance, including the lower bound of a 99% confidence interval. We considered 16 of the 20 MEC medical conditions; we excluded malignant gestational trophoblastic disease, liver cancer, schistosomiasis, and solid organ transplant because the number of women with these conditions was less than 11.

Rate analysis
-------------

Because rates for FPM and HEM use increased nationally during the years of our study, we used rates in the overall population as a scaling factor for the study population. The scaling factor was applied to the study population use rate to accurately determine the change in rates before and after the introduction of MEC.

A 1-sided exact Poisson test was used to determine whether provision of contraception increased significantly in the study population. The alternative hypothesis was defined as the before-MEC rate being smaller than the after-MEC rate. A ratio greater than 1 indicates an increase in provision; a ratio of 1.1 indicates a 10% increase in the rate.

The test statistic comparing before-MEC and after-MEC outcome measures was scaled by the rates in each of the 2 periods by the corresponding outcome measure of the overall population ([Appendix B](#appB){ref-type="app"}). The test procedure was applied to all conditions together and to each MEC condition separately. For the condition-level analysis, we corrected for the testing of multiple outcomes simultaneously by using the Bonferroni correction.

Results
=======

Study population
----------------

Our sample consisted of more than 12 million women in 14 states who were covered by Medicaid in both study periods ([Table 1](#T1){ref-type="table"}). Most reproductive-aged women enrolled in Medicaid did not have claims for these conditions; less than 5% were identified as having 1 of the 20 high-risk MEC conditions. Though low, we saw an increase from 3.5% in the before-MEC period to 3.9% in the after-MEC period. More than half of the women with high-risk conditions were in the 35-to-44 age group, 53.5% in the before-MEC period and 66.9% in the after-MEC period. The 4 most common conditions made up 83% of the study population; in order of frequency, they were hypertension, diabetes, epilepsy, and HIV.

###### Reproductive-Aged Women in Medicaid Study Population Before and After MEC, by Age, State of Residence, and Health Condition

  Variable                                                 State Population Before MEC, 2008--2009, N = 442,424   State Population After MEC, 2011--2012, N = 533,619
  -------------------------------------------------------- ------------------------------------------------------ -----------------------------------------------------
  **Overall population, N**                                12,422,899                                             13,597,612
  **Study population[a](#T1FN1){ref-type="table-fn"}**     437,018 (3.5)                                          527,660 (3.9)
  **Age[b](#T1FN2){ref-type="table-fn"}, y**                                                                      
  15--24                                                   69,050 (15.8)                                          87,797 (16.6)
  25--34                                                   134,267 (30.7)                                         200,909 (38.1)
  35--44                                                   233,701 (53.5)                                         352,833 (66.9)
  **State[b](#T1FN2){ref-type="table-fn"}**                                                                       
  Alabama                                                  16,312 (3.7)                                           18,721 (3.5)
  Arkansas                                                 10,310 (2.3)                                           11,750 (2.2)
  California                                               84,653 (19.1)                                          96,830 (18.1)
  Florida                                                  41,298 (9.3)                                           54,755 (10.3)
  Georgia                                                  31,543 (7.1)                                           32,481 (6.1)
  Louisiana                                                23,031 (5.2)                                           25,568 (4.8)
  Minnesota                                                11,389 (2.6)                                           16,844 (3.2)
  Mississippi                                              17,284 (3.9)                                           18,888 (3.5)
  New York                                                 70,602 (16.0)                                          97,243 (18.2)
  North Carolina                                           40,180 (9.1)                                           41,878 (7.8)
  Pennsylvania                                             10,374 (2.3)                                           18,615 (3.5)
  South Carolina                                           15,134 (3.4)                                           20,439 (3.8)
  Tennessee                                                32,329 (7.3)                                           34,784 (6.5)
  Texas                                                    37,985 (8.6)                                           44,823 (8.4)
  **Medical conditions[c](#T1FN3){ref-type="table-fn"}**                                                          
  Bariatric surgery                                        5,158 (1.0)                                            6,726 (1.1)
  Breast cancer                                            11,072 (2.1)                                           13,016 (2.1)
  Diabetes                                                 159,042 (30.4)                                         190,648 (30.1)
  Endometrial and ovarian cancer                           2,259 (0.4)                                            2,557 (0.4)
  Epilepsy                                                 43,213 (8.3)                                           55,666 (8.8)
  Malignant gestational trophoblastic disease              118 (0.0)                                              123 (0.0)
  Human immunodeficiency virus                             23,865 (4.6)                                           22,894 (3.6)
  Hypertension                                             207,286 (39.7)                                         259,571 (40.9)
  Ischemic heart disease                                   12,357 (2.4)                                           13,577 (2.1)
  Liver cancer                                             273 (0.1)                                              342 (0.1)
  Lupus                                                    15,750 (3.0)                                           20,014 (3.2)
  Schistosomiasis                                          120 (0.0)                                              ---[d](#T1FN4){ref-type="table-fn"}
  Solid organ transplant                                   588 (0.1)                                              578 (0.1)
  Peripartum cardiomyopathy                                2,817 (0.5)                                            3,024 (0.5)
  Sickle cell disease                                      8,395 (1.6)                                            9,564 (1.5)
  Severe cirrhosis                                         6,626 (1.3)                                            9,451 (1.5)
  Stroke                                                   8,090 (1.5)                                            9,612 (1.5)
  Thrombogenic heart disease                               4,944 (0.9)                                            5,645 (0.9)
  Tuberculosis                                             2,938 (0.6)                                            2,469 (0.4)
  Valvular heart disease                                   7,645 (1.5)                                            8,630 (1.4)

Values are number (percentage) unless otherwise indicated. Percentage is the study population (women with a high-risk condition) relative to the overall population. Denominators of percentages vary because some women had more than one disorder.

The Southeastern states were chosen as a focal point because of their similarity to each other in contraception health policy ([@R12]) and spending levels for Medicaid ([@R13]). In addition, the health rankings of these states are among the lowest in the country ([@R14]). The other 4 states chosen (California, Minnesota, New York, and Pennsylvania) were highly populous states from regions of the country that have various health policies and reimbursement levels that represent differences across the United States.

Percentage is stratification group relative to sum of women in that strata. The sum of all categories in the stratification group may be greater than the total study population; women can belong to more than 1 category in the same stratification. Medical conditions totals used are 522,556 and 634,107, before and after MEC phases respectively. Medical conditions are the 20 disorders identified in the 2010 Centers for Disease Control and Prevention's US Medical Eligibility Criteria for Contraceptive Use that increase risk for adverse outcomes in pregnancy ([@R1]).

Total population was fewer than 11. The Centers for Medicare and Medicaid Services data use agreement does not allow publication of results when study population (eg, patients) is fewer than 11 participants.

Outcome analysis
----------------

**FPM outcome: aggregate and condition-level analysis.**Provision of FPM for all reproductive-aged women in Medicaid increased from 17.9% before MEC to 18.2% after MEC. We saw a comparable increase for women in the study population, from 16.7% before MEC to 17.8% after MEC ([Table 2](#T2){ref-type="table"}) (estimate: 1.06; lower bound CI: 1.05). Provision of FPM varied by medical condition, ranging from 4.4% before MEC and 6.7% after MEC for those with liver cancer to 46.6% before MEC and 44.8% after MEC for those with peripartum cardiomyopathy. The conditions with the highest rates of FPM provision for both periods were peripartum cardiomyopathy, sickle cell disease, and thrombogenic heart disease ([Figure 1](#F1){ref-type="fig"}). Gestational trophoblastic disease had the second highest provision of FPM before MEC.

###### Provision of Family Planning Management (FPM) for Reproductive-Aged Women with Medical Conditions Enrolled in Medicaid in the 2-Year Period Before (2008 and 2009) and 2-Year Period After (2011 and 2012) the 2010 Release of the US Medical Eligibility Criteria for Contraceptive Use (MEC)

  Family Planning Management[a](#T2FN1){ref-type="table-fn"}   Total Before MEC, 2008--2009[a](#T2FN1){ref-type="table-fn"}   FPM Provision Before MEC, 2008--2009[a](#T2FN1){ref-type="table-fn"}   Total After MEC, 2011--2012[a](#T2FN1){ref-type="table-fn"}   FPM Provision After MEC, 2011--2012[a](#T2FN1){ref-type="table-fn"}   Estimate[b](#T2FN2){ref-type="table-fn"} (Lower Bound CI[c](#T2FN3){ref-type="table-fn"})   P Value[d](#T2FN4){ref-type="table-fn"}
  ------------------------------------------------------------ -------------------------------------------------------------- ---------------------------------------------------------------------- ------------------------------------------------------------- --------------------------------------------------------------------- ------------------------------------------------------------------------------------------- -----------------------------------------
  **Overall population**                                       12,422,899                                                     2,221,325 (17.9)                                                       13,597,612                                                    2,477,023 (18.2)                                                      NA                                                                                          NA
  **Study population**                                         437,018                                                        87,115 (16.7)                                                          527,660                                                       112,851 (17.8)                                                        1.06 (1.05)                                                                                 \<.001
  **Medical conditions**                                                                                                                                                                                                                                                                                                                                                                                                             
  Bariatric surgery                                            5,158                                                          650 (12.6)                                                             6,726                                                         1,265 (18.8)                                                          1.49 (1.42)                                                                                 \<.001
  Breast cancer                                                11,072                                                         822 (7.4)                                                              13,016                                                        1117 (8.6)                                                            1.16 (1.13)                                                                                 \<.001
  Diabetes                                                     159,042                                                        26,915 (16.9)                                                          190,648                                                       33,928 (17.8)                                                         1.05 (1.04)                                                                                 \<.001
  Endometrial and ovarian cancer                               2,259                                                          105 (4.6)                                                              2,557                                                         187 (7.3)                                                             1.58 (1.48)                                                                                 \<.001
  Epilepsy                                                     43,213                                                         8,104 (18.8)                                                           55,666                                                        10,469 (18.8)                                                         1.00 (0.98)                                                                                 .55
  Human immunodeficiency virus                                 23,865                                                         2,816 (11.8)                                                           22,894                                                        3,549 (15.5)                                                          1.31 (1.28)                                                                                 \<.001
  Hypertension                                                 207,286                                                        35,681 (17.2)                                                          259,571                                                       47,465 (18.3)                                                         1.07 (1.06)                                                                                 \<.001
  Ischemic heart disease                                       12,357                                                         1,049 (8.5)                                                            13,577                                                        1,331 (9.8)                                                           1.15 (1.12)                                                                                 \<.001
  Liver cancer                                                 273                                                            12 (4.4)                                                               342                                                           23 (6.7)                                                              1.52 (1.25)                                                                                 \<.001
  Lupus                                                        15,750                                                         2,731 (17.3)                                                           20,014                                                        3,830 (19.1)                                                          1.10 (1.07)                                                                                 \<.001
  Malignant gestational trophoblastic disease                  118                                                            32 (27.1)                                                              123                                                           22 (17.9)                                                             0.66 (0.49)                                                                                 .99
  Peripartum cardiomyopathy                                    2817                                                           1,312 (46.6)                                                           3.024                                                         1,355 (44.8)                                                          0.96 (0.90)                                                                                 .95
  Severe cirrhosis                                             6626                                                           769 (11.6)                                                             9,451                                                         1,275 (13.5)                                                          1.16 (1.12)                                                                                 \<.001
  Sickle cell disease                                          8,395                                                          1,996 (23.8)                                                           9,564                                                         2,337 (24.4)                                                          1.03 (1.00)                                                                                 .02
  Solid organ transplant                                       588                                                            36 (6.1)                                                               9,612                                                         74 (12.8)                                                             2.14 (1.86)                                                                                 \<.001
  Stroke                                                       8,090                                                          922 (11.4)                                                             5,645                                                         1,224 (12.7)                                                          1.12 (1.08)                                                                                 \<.001
  Thrombogenic heart disease                                   4,944                                                          1,200 (24.3)                                                           2,469                                                         1,335 (23.6)                                                          0.97 (0.93)                                                                                 .94
  Tuberculosis                                                 2,938                                                          564 (19.2)                                                             8,630                                                         481 (19.5)                                                            1.02 (0.96)                                                                                 .24
  Valvular heart disease                                       7,645                                                          1,399 (18.3)                                                           9,612                                                         1,584 (18.4)                                                          1.00 (0.96)                                                                                 .52

Abbreviation: CI, confidence interval; NA, not applicable.

Values are number (percentage). Percentage is number of women with an FPM claim relative to women in that disease category. FPM claim includes all claims with an ICD-9 (*International Classification of Disease, Ninth Revision*)([@R17]) code that begins with V25.

The estimate is the ratio of the after-MEC scaled rate to the before-MEC scaled rate. A ratio greater than 1 indicates an increase in provision; a ratio of 1.1 indicates a 10% increase in the rate.

1-sided 99% confidence interval.

*P*values are based on 1-sided Poisson test at a 99% confidence level. Bonferroni adjustment for *P*value threshold is .003.

![Changes in percentage of women, by medical condition, with a Medicaid claim for family planning management from the 2-year period before (2008 and 2009) to the 2-year period after (2011 and 2012) the 2010 release of the US Medical Eligibility Criteria for Contraceptive Use (MEC) by the Centers for Disease Control and Prevention ([@R1]). Percentage is number of women with each medical condition and an FPM Medicaid claim relative to the total population for that condition.](PCD-16-E03s01){#F1}

Before and after the MEC release, 12 of the 19 conditions examined showed a significant increase at the 1% significance level. After accounting for the increase at the overall population level, 5 conditions showed a greater than 30% increase in FPM: bariatric surgery, endometrial and ovarian cancer, HIV, liver cancer, and solid organ transplant ([Table 2](#T2){ref-type="table"}). The 7 conditions that did not show a significant increase in FPM were epilepsy, malignant gestational trophoblastic disease, peripartum cardiomyopathy, sickle cell disease, thrombogenic heart disease, tuberculosis, and valvular heart disease ([Table 2](#T2){ref-type="table"}).

**HEM outcome: aggregate and condition-level analysis.** Of the 12,422,899 reproductive-aged women insured by Medicaid, 437,036 had a HEM claim (3.5% ) before MEC's release; 679,230 of the 13,597,612 women (5.0%) insured by Medicaid had a HEM claim after MEC ([Table 3](#T3){ref-type="table"}) (estimate: 1.37; lower bound CI: 1.36). We saw a comparable increase for women in the study population, from 4.1% to 5.7%. Provision of HEM varied by medical condition in both periods, ranging from 0.9% before MEC for endometrial or ovarian cancer to 25.6% after MEC for peripartum cardiomyopathy ([Figure 2](#F2){ref-type="fig"}). After accounting for the increase at the overall population level, all 16 conditions showed a significant increase at the 1% significance level ([Table 3](#T3){ref-type="table"}). HEM provision more than doubled for 2 conditions: bariatric surgery and endometrial and ovarian cancer.

###### Provision of Highest Efficacy Contraception Methods (HEM)[a](#T3FN1){ref-type="table-fn"} for Reproductive-Aged Women with Medical Conditions Enrolled in Medicaid in the 2-Year Period Before (2008 and 2009) and 2-Year Period After (2011 and 2012) the 2010 Release of the US Medical Eligibility Criteria for Contraceptive Use (MEC)

  Conditions Requiring Highest Efficacy Methods   Total Before MEC, 2008--2009[a](#T3FN1){ref-type="table-fn"}   HEM Provision Before MEC, 2008--2009[a](#T3FN1){ref-type="table-fn"}   Total After MEC, 2011--2012[a](#T3FN1){ref-type="table-fn"}   HEM Provision After MEC, 2011--2012[a](#T3FN1){ref-type="table-fn"}   Estimate[b](#T3FN2){ref-type="table-fn"} (Lower Bound CI[c](#T3FN3){ref-type="table-fn"})   *P* Value[d](#T3FN4){ref-type="table-fn"}
  ----------------------------------------------- -------------------------------------------------------------- ---------------------------------------------------------------------- ------------------------------------------------------------- --------------------------------------------------------------------- ------------------------------------------------------------------------------------------- -------------------------------------------
  Overall population                              12,422,899                                                     437,036 (3.5)                                                          13,597,612                                                    679,230 (5.0)                                                         NA                                                                                          NA
  Study population                                437,018                                                        21,413 (4.1)                                                           527,660                                                       36,176 (5.7)                                                          1.37 (1.36)                                                                                 .001
  Bariatric surgery                               5,158                                                          114 (2.2)                                                              6,726                                                         416 (6.2)                                                             2.8 (2.68)                                                                                  .001
  Breast cancer                                   11,072                                                         214 (1.9)                                                              13,016                                                        400 (3.1)                                                             1.59 (1.55)                                                                                 .001
  Diabetes                                        159,042                                                        6,892 (4.3)                                                            190,648                                                       11,377 (6.0)                                                          1.38 (1.37)                                                                                 .001
  Endometrial and ovarian cancer                  2,259                                                          21 (0.9)                                                               2,557                                                         58 (2.3)                                                              2.43 (2.27)                                                                                 .001
  Epilepsy                                        43,213                                                         1,658 (3.8)                                                            55,666                                                        2,813 (5.1)                                                           1.32 (1.30)                                                                                 .001
  Human immunodeficiency virus                    23,865                                                         602 (2.5)                                                              22,894                                                        976 (4.3)                                                             1.69 (1.65)                                                                                 .001
  Hypertension                                    207,286                                                        8,902 (4.3)                                                            259,571                                                       15,072 (5.8)                                                          1.35 (1.34)                                                                                 .001
  Ischemic heart disease                          12,357                                                         242 (2.0)                                                              13,577                                                        439 (3.2)                                                             1.65 (1.60)                                                                                 .001
  Lupus                                           15,750                                                         615 (3.9)                                                              20,014                                                        1,187 (5.9)                                                           1.52 (1.48)                                                                                 .001
  Peripartum cardiomyopathy                       2,817                                                          559 (19.8)                                                             3,024                                                         775 (25.6)                                                            1.29 (1.21)                                                                                 .001
  Severe cirrhosis                                6,626                                                          159 (2.4)                                                              9,451                                                         391 (4.1)                                                             1.72 (1.66)                                                                                 .001
  Sickle cell disease                             8,395                                                          302 (3.6)                                                              9,564                                                         511 (5.3)                                                             1.49 (1.44)                                                                                 .001
  Solid organ transplant                          588                                                            ---[e](#T3FN5){ref-type="table-fn"}                                    578                                                           24 (4.2)                                                              NA                                                                                          NA
  Stroke                                          8,090                                                          237 (2.9)                                                              9,612                                                         452 (4.7)                                                             1.60 (1.55)                                                                                 .001
  Thrombogenic heart disease                      4,944                                                          423 (8.6)                                                              5,645                                                         576 (10.2)                                                            1.19 (1.14)                                                                                 .001
  Tuberculosis                                    2,938                                                          102 (3.5)                                                              2,469                                                         146 (5.9)                                                             1.71 (1.61)                                                                                 .001
  Valvular heart disease                          7,645                                                          371 (4.9)                                                              8,630                                                         563 (6.5)                                                             1.35 (1.30)                                                                                 .001

Abbreviations: CI, confidence interval; NA, not applicable.

Values are number (percentage). Percentage is number of women with an HEM Medicaid claim relative to the population in that disease category. HEM claims for contraception are for intrauterine devices, contraceptive implants, and sterilization.

Estimated ratio of the after-MEC scaled rate to the before-MEC scaled rate. A ratio greater than 1 indicates an increase in provision; a ratio of 1.1 indicates a 10% increase in the rate.

1-sided 99% confidence interval.

*P* values are based on 1-sided Poisson test at 99% confidence level. Bonferroni adjustment for *P* value threshold is *P* \< .006.

Total population was fewer than 11. The Centers for Medicare and Medicaid Services Data Use Agreement does not allow publication of results when study population (eg, patients) is fewer than 11 participants.

![Changes in percentage of women, by medical condition, with a Medicaid claim for a highest efficacy contraception method from the 2-year period before (2008 and 2009) to the 2-year period after (2011 and 2012) the 2010 release of the US Medical Eligibility Criteria for Contraceptive Use (MEC) by the Centers for Disease Control and Prevention ([@R1]). Highest efficacy methods are contraceptive implants, intrauterine devices, and sterilization. Percentage is number of women with each medical condition and an HEM Medicaid claim relative to the total population for that condition.](PCD-16-E03s02){#F2}

Discussion
==========

Our study showed an overall increase in provision of FPM and HEM from the 2-year period before MEC's release to the 2-year period after its release for women with 1 or more of the 20 medical conditions MEC identified as high risk for pregnant women. When all conditions were considered together, the difference was significant for both FPM and HEM. For individual conditions, significance was found for FPM for most medical conditions and for HEM for all medical conditions. The increase in HEM provision mirrors national trends. According to an analysis by the National Survey of Family Growth, the use of IUDs and contraceptive implants among reproductive-aged American women increased from 6% in 2008 to 12% in 2012 ([@R18]). Although our study accounted for the increase seen in the overall population and documented an increase across medical conditions, HEM rates for women with 1 or more of the 20 conditions were below the national average. Champaloux and colleagues had a similar finding in their review of claims of women with medical conditions from a privately insured population ([@R19]).

HEMs are particularly important for women with MEC-identified medical conditions, because pregnancy can result in severe adverse health outcomes for this population. The physiologic changes of pregnancy affect nearly every organ system in the body. For example, normal pregnancy creates a state of anemia, increased oxygen demand and cardiac output, hypercoagulability, immune compromise, and insulin resistance. These necessary changes support gestation and are generally well tolerated by healthy women. However, women with underlying medical conditions may experience amplification of their condition or predisposition to complications and illness, including death ([@R20]). The maternal death rate in the United States is the highest in the developed world ([@R21]). A recent review of maternal deaths from 9 states identified hemorrhage, cardiovascular and coronary conditions, infection, and cardiomyopathy as the most common causes ([@R22]). The review identified age-related differences underlying the cause of death and estimated that 63.2% of these deaths were preventable. One step proximal to preventing maternal death is preventing maternal illness. To prevent increased risk associated with pregnancy, a woman with a high-risk medical condition should have ready access to the most effective methods of contraception until she desires pregnancy. Then, when planning to conceive, a woman should have access to preconception care to optimize her health, manage medications, and transition her to and through pregnancy. This approach will help women with high-risk conditions to attain their reproductive goals while decreasing their health risk ([@R23]).

Our study found that provision of FPM and HEM varied by medical condition. For example, we found lower rates for FPM and HEM relative to other medical conditions among women with cancer (breast, endometrial, and ovarian cancer). One explanation is the nature of these conditions and the methods used to treat them. For example, hysterectomies or bilateral oophorectomies are common forms of treatment for endometrial and ovarian cancer, eliminating the need for contraception. Where the ability to conceive remains intact, cancers can limit women's contraceptive options. For example, IUDs are contraindicated for women with endometrial cancer as are hormonal IUDs and implants for women with breast cancer ([@R1]). On the other hand, we found that peripartum cardiomyopathy had the highest rates of FPM and HEM. One possible reason is that this condition is associated with high rates of illness and death rates as high as 14% for a subsequent pregnancy ([@R24]). Second, by definition, peripartum cardiomyopathy is diagnosed in the last month of pregnancy or the first few months after delivery. The timing of the diagnosis may create the opportunity for a health care provider to educate a woman on the importance of contraception because of the high risk associated with a subsequent pregnancy. However, the medical conditions affecting most women fall in between these extremes. Hypertension, diabetes, epilepsy, and HIV affected more than 430,000 women in our study, and these conditions also put women at high risk for adverse health outcomes with pregnancy. Therefore, additional focus should also be placed on these conditions.

Our study had several limitations. CMS data restricted us to the clinician's diagnosis and procedure coding during the visit. Therefore, we may not have captured data on women using contraception methods that did not require a clinician or using methods for uncoded services. For example, we may not have captured data on women with previously placed IUDs or implants if surveillance of these devices was not coded during an annual or other visit. Similarly, we were only able to reliably capture data on sterilization procedures that occurred during the years of our study. Hence, data were not captured on women who used tubal sterilization and partner vasectomy as a form of birth control. For these reasons, we believe our findings to be underestimates. Because claims data do not include sexual or relationship history, we were unable to ascertain whether a woman was at risk for pregnancy on the basis of sexual activity with a male partner, nor were we able to assess whether her medical condition precluded sexual activity or fertility. Medicaid eligibility criteria for women vary by state, and women who become pregnant may be eligible for Medicaid for a limited amount of time. For 2 common conditions, hypertension and diabetes, MEC guidelines apply to women with severe disorders; our analysis was more inclusive by showing all women with the disorders. Finally, our statistical analysis shows associations but cannot directly address causality or reasons for a change.

Overall, our study found a limited, but encouraging, change in clinical practice in the 2 years after the release of MEC guidelines. The relatively low rate of FPM and provision of HEM that we found suggests that access to highly effective contraceptives was a barrier. Access issues for contraception can arise from financial and systems issues as well as from provider bias ([@R25]). Such barriers may also present opportunities for ongoing and future steps toward full implementation of MEC guidelines.

Historically, access to contraception has been limited, especially for low-income women ([@R26]). Several efforts were made to lessen financial and system barriers to accessing contraception after the 2010 release of the MEC. After the Affordable Care Act mandate for contraceptive coverage went into effect, the percentage of women using IUDs and implants increased among sexually active women, whereas the use of oral contraception remained flat ([@R27]). The 6\|18 Initiative ([@R28]) of CDC and its partners outlined 4 interventions for reducing financial and logistic barriers for public and private payers and providers. For women with no insurance coverage, family planning services can be obtained from the Federal Title X grant ([@R29]). These multilevel and collaborative approaches to reducing barriers may serve to increase the uptake of the MEC guidelines ([@R30]). In addition to these interventions, parallel programs have been working to ensure provider knowledge and application of MEC in practice. These include endorsement and implementation support of MEC by several medical associations, including the American College of Obstetricians and Gynecologists and the American Academy of Family Physicians ([@R31],[@R32]). Focusing future efforts on specialist health care providers may help ensure that women with high-risk medical conditions receive evidence-based care and referrals to contraception counseling.
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  Condition                                                          ICD-9 Code
  ------------------------------------------------------------------ -------------------------------------------
  Breast cancer                                                      174
  Diabetes                                                           250
  Endometrial and ovarian cancer                                     179, 182, 183
  Epilepsy                                                           345
  History of bariatric surgery (past 2 years) ^a^                    V45.86
  Human immunodeficiency virus                                       042
  Hypertension                                                       401--405
  Ischemic heart disease                                             410, 412--414
  Malignant gestational trophoblastic disease                        181
  Malignant liver tumors and hepatocellular carcinoma of the liver   155
  Peripartum cardiomyopathy                                          674.5
  Schistosomiasis with fibrosis of the liver                         120.9
  Severe cirrhosis                                                   571
  Sickle cell disease                                                282.6
  Solid organ transplant in the past 2 years^b^                      V42.0, V42.1, V42.6, V42.7, V42.83, V42.9
  Stroke                                                             430--434, 436--438
  Systemic lupus erythematosus                                       710.0
  Thrombogenic mutations                                             286\.
  Tuberculosis                                                       010--018
  Valvular heart disease                                             424

^a^ *International Classification of Disease, Ninth Revision*([@R17]).

^b^ Current Procedural Terminology code; used to identify surgical medical conditions ([@R16]).

Setting up the problem, we define:

*C* ~i~ ^k^: Total number of women in overall population in time period *i* for outcome *k*

*C* ~i~ = Sum of C~i~ ^k^ for all k = Total overall population in time period *i*
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Given that *M~i~* is a subset of the overall population, the expected number of women in the study population with outcome *k* is
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Furthermore, let
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Scaled proportion of the study population for time period i and medical condition j

where:

phase
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∈ (0,1)

medical condition j ∈ (1,2,...20)

outcome

k

∈ (1,2)

We determined the rate for each time-period as:

-   Outcome 1: family planning management (FPM) ratio

-   Counseling, insertions, and surveillance for contraceptive methods

-   Outcome 2: highest efficacy method (HEM) ratio

-   Intrauterine device (IUD): insertion and surveillance

-   Implants: insertion

The ratio of rates in time period 0 and time period 1 were assessed by using a 1-sided exact Poisson test.
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All analysis was completed by using R version 3.4.3 (<https://www.r-project.org/>).
